Prevalence and determinants of iron deficiency in cardiac amyloidosis.
Dr Benoît LEQUEUX : Cardiologue CHU de Poitiers Prevalence and determinants of iron deficiency in cardiac amyloidosis. https://pubmed.ncbi.nlm.nih.gov/35128833/. PMID : 35128833
Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Pr François TOURNOUX : Cardiologue – CHU de Montréal CANADA Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS). https://pubmed.ncbi.nlm.nih.gov/35451899/ PMID : 35451899
Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression.
Dr Eve CARIOU – Cardiologue CHU de Toulouse Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression. https://pubmed.ncbi.nlm.nih.gov/33129740/ PMID : 33129740
Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT])
Dr Zoubida TAZI MEZALEK – Cardiologue CHU de Rabat MAROC Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]) https://pubmed.ncbi.nlm.nih.gov/33667442/ PMID : 33667442
Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis.
Dr Martin NICOL : Cardiologue APHP Lariboisière – Paris https://pubmed.ncbi.nlm.nih.gov/35292807/ PMID : 35292807
Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
Dr Clément BECLE Cardiologique – Centre Cardiologique de l’Ouest Lyonnais – Lyon https://pubmed.ncbi.nlm.nih.gov/33220323/ PMID : 33220323
The role of serial (99m)Tc-DPD scintigraphy in monitoring cardiac transthyretin amyloidosis
Pierre TROISFONTAINES – Cardiologue CHR de la Citadelle Liège – BELGIQUE The role of serial (99m)Tc-DPD scintigraphy in monitoring cardiac transthyretin amyloidosis. https://pubmed.ncbi.nlm.nih.gov/34704883/ PMID : 34704883
Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT.
Erwan DONAL : cardiologue CHU de Rennes Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT. https://pubmed.ncbi.nlm.nih.gov/34509404/ PMID : 34509404
Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation.
Thibaut WAJCHERT – Dr Junior au CHU de Versailles Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation. https://pubmed.ncbi.nlm.nih.gov/32981389/ PMID : 32981389
Impact of tricuspid regurgitation on survival in patients with cardiac amyloidosis
Damien EYHARTS – cardiologue CHU de Toulouse Impact of tricuspid regurgitation on survival in patients with cardiac amyloidosis https://pubmed.ncbi.nlm.nih.gov/34643339/ PMID : 34643339
